Clinical Cancer Investigations Committee (CCIC)
The Clinical Cancer Investigations Committee (CCIC) was created in 1993 to comply with National Cancer Institute Cancer Center guidelines to establish a protocol review and monitoring system of cancer studies-it is a mechanism for quality assurance. It includes 15 faculty members from various disciplines within the Health Sciences.
The CCIC is responsible for reviewing cancer-related protocols for scientific merit (before a protocol is activated), scientific progress (after the protocol has been initiated) and participant accrual. It also prioritizes cancer protocols that may be competing for the same participant population.
If your study is designed to involve cancer patients, it must receive CCIC approval before it can be IRB approved. If your study may include cancer patients by default (as part of a broader patient population) and not by study design, it does not need CCIC review.
Industry-designed and national cooperative group trials can be reviewed by the CCIC and IRB simultaneously. Investigator-initiated cancer projects must first be reviewed and approved by the CCIC and then reviewed and approved by the IRB.
What should I submit? Indicate that your study involves cancer patients in the HIPAA section of the New Study Application in ERICA. This action will automatically prompt ERICA to generate the CCIC Cover Sheet.
For more information about CCIC, please see the CCIC New Study Information Sheet.